注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Mesoblast Ltd是一家從事危重炎症同種異體細胞藥物研發的公司。該公司利用其間充質譜系細胞技術平台開發同種異體細胞藥物,並將其商業化,用以治療複雜的炎症疾病。其候選藥品包括Remestemcel-L(RYONCIL)用於治療類固醇難治性急性移植物抗宿主病(SR-aGVHD)、Rexlemestrocel-L(REVASCOR)用於治療晚期慢性心力衰竭(CHF),MPC-06-ID用於治療腰椎椎間盤退化(CLBP)引起的慢性腰痛,其候選藥品MPC-150-IM用於治療或預防慢性心力衰竭,MPC-25-IC用於治療或預防急性心肌梗塞。該公司候選藥品還包括MPC-300-IV,用於治療生物難治性類風濕性關節炎和糖尿病腎病。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Joseph R. Swedish | 69 | 2018 | Independent Non-Executive Chairman |
William A. M. Burns | 72 | 2014 | Independent Non-Executive Vice Chairman |
Silviu Itescu | 64 | 2004 | Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director |
Eric A. Rose | 71 | 2013 | Chief Medical Officer & Executive Director |
Henry Krum | - | - | Member of Scientific Advisory Board |
Robert M. Graham | - | - | Member of Scientific Advisory Board |
Stephen Graves | - | - | Member of Scientific Advisory Board |
Joseph M. Lane | - | - | Member of Scientific Advisory Board |
Richard E. Gilbert | - | - | Member of Scientific Advisory Board |
Philip James Facchina | 61 | 2021 | Independent Non-Executive Director |
Philip R. Krause | - | 2022 | Non Executive Director |
Jane Catherine Bell | - | 2022 | Independent Non-Executive Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核